AR054224A1 - Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 - Google Patents
Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3Info
- Publication number
- AR054224A1 AR054224A1 AR20060100549A ARP060100549A AR054224A1 AR 054224 A1 AR054224 A1 AR 054224A1 AR 20060100549 A AR20060100549 A AR 20060100549A AR P060100549 A ARP060100549 A AR P060100549A AR 054224 A1 AR054224 A1 AR 054224A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- cycloalkyl
- aryl
- alkylaryl
- heterocyclyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente describe un compuesto o enantiomeros, estereoisomeros, rotámeros, tautomeros, racematos o un profármaco de dicho compuesto o sales aceptables para uso farmacéutico. También se describe un método para tratar enfermedades mediadas por quimiocinas, tales como terapia paliativa, terapia curativa, terapia profiláctica de ciertas enfermedades y afecciones tales como enfermedades inflamatorias (ejemplo(s) no limitativo(s) incluye(n), psoriasis), enfermedades autoinmunes (ejemplo(s) no limitativo(s) incluye(n), artritis reumatoidea, esclerosis multiple). Reivindicacion 1: Un compuesto que posee la estructura general de Formula (1); o sales aceptables para uso farmacéutico, solvatos o ésteres de los mismos, donde: X es N, O, alquilo, cicloalquilo, heteroarilo, heterociclilo o heterociclenilo; el anillo D es un anillo fenilo no sustituido o sustituido opcionalmente por restos R20 seleccionados independientemente segun se indica a continuacion; R1 y R2 se encuentran ausentes o presentes de manera Independiente, y si se encuentran presentes, cada uno se selecciona independientemente del grupo que consiste en H, alquilo, alcoxi, alquenilo, carbonilo, cicloalquilo, alquilcicloalquilo-, cicloalquenilo, alquilarilo, arilalquilo, arilo, amino, alquilamino, amidinilo, carboxamido, ciano, hidroxilo, urea, -NsCH, =NCN, -(CH2)qOH, (CH2)qOR31, (CH2)qNH2, (CH2)qNHR31, (CH2)qN(R31)2, (CH2)qC(=O)NHR31, (CH2)qSO2R31, (CH2)qNHSO2R31, (CH2)qSO2NHR31, -C(=S)N(H)alquilo, - N(H)-S(O)2-alquilo, -N(H)C(=O)N(H)-alquilo, -S(O)2-alquilo, -S(O)2N(H)-alquilo, -S(O)2N(alquilo)2, -S(O)2-arilo, -C(=S)N(H)-cicloalquilo, -C(=O)N(H)NH2, -C(=O)-alquilo, -heteroarilo, heterociclilo y heterociclenilo; o de manera alternativa cuando X es N, el N tomado junto con el R1 y R2 forma un heterociclilo, heteroarilo o -N=C(NH2)2; R3 y R6 restos pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, aralquilo, -CN, CF3, haloalquilo, cicloalquilo, halogeno, hidroxialquilo, -N=CH-(R31), -C(O)N(R30)2, -N(R30)2, -OR30, -SO2(R31), -N(R30)C(=O)N(R30)2 y -N(R30)C(=O)R31; R7 y R8, son iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, heteroarilo, hidroxilo, -CN, alcoxi, alquilamino, -N(H)S(O)2-alquilo y -N(H)C(=O)N(H)-alquilo; o de manera alternativa R7 y R8 tomados juntos son =O, S, =NH, =N(alquilo), =N(O-alquilo), =N(OH) o cicloalquilo; los restos R10 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclenilo, heterociclilo, alquilarilo, arilalquilo, -CO2H, hidroxialquilo, - C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31, -(CH2)qNHR31, (CH2)qN(R31)2, -OR30, halogeno, =O y -C(=O)R31; los restos R11 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, cicloalquilo, arilo, heteroarilo, heterociclilo, heterociclenilo, alquilarilo, arilalquilo, hidroxialquilo, carboxamida, CO2H, (CH2)qOH, (CH2)qOR31, (CH2)qNHR31, (CH2)qN(R31)2, -OR30, halogeno, =O y -C(=O)R31; R12 se selecciona del grupo que consiste en H, alquilo, -CN, -C(=O)N(R30)2, -(CH2)qOH, -(CH2)qOR31, (CH2)qNHR31, (CH2)qN(R31)2 y -S(O2)R31; los restos R20 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, haloalcoxi, hidroxamato, nitro, trifluorometilo, trifluorometoxi, -(CH2)qOH, -(CH2)qOR31, (CH2)qNH2, (CH2)qNHR31, (CH2)qN(R31)2, (CH2)qC(=O)NHR31, (CH2)qSO2R31, (CH2)qNHSO2R31, (CH2)qSO2NHR31, -alquinilo C(R31)2OR31, -C(=O)R30, -C(=O)NR(30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, -C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, - NHC(=O)N(R30)2, -N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(=O)N(R30)SO2(R31), -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), -N(R30)S(O)2N(R30)2, -OR30, -OC(=O)N(R30)2, -SR30, .SO2N(R30)2, SO2(R31), -OSO2(R31), O(CH2)qSO2R31 y -OSi(R30)3 o de manera alternativa dos R20 restos se unen para formar un anillo arilo, cicloalquilo, heterociclilo, heterociclenilo o heteroarilo de cinco o seis miembros donde dicho anillo arilo, cicloalquilo, heterociclilo, heterociclenilo o heteroarilo de cinco o seis miembros se fusiona al anillo D y el anillo fusionado se sustituye opcionalmente con 0-4 restos R21; los restos R21 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquenilo, alquilarilo, alquinilo, alcoxi, alquilamino, alquiltiocarboxi, alquilheteroarilo, alquiltio, alquilsulfinilo, alquilsulfonilo, alcoxicarbonilo, aminoalquilo, amidinilo, aralquilo, aralquenilo, aralcoxi, aralcoxicarbonilo, aralquiltio, arilo, aroilo, ariloxi, carboxamido, ciano, cicloalquilo, cicloalquenilo, formilo, guanidinilo, halogeno, haloalquilo, heteroalquilo, heteroarilo, heterociclilo, heterociclenilo, hidroxialquilo, hidroxamato, nitro, trifluorometoxi, -(CH2)qOH, -(CH2)qOR31, - (CH2)qNH2, -(CH2)qNHR31, -(CH2)qN(R31)2, -(CH2)C(=O)NHR31, (CH2)qSO2R31, -(CH2)qNSO2R31, -(CH2)qSO2NHR31, -alquinilo C(R31)2OR31, -C(=O)R30, -C(=O)N(R30)2, -C(=NR30)NHR30, -C(=NOH)N(R30)2, -C(=NOR31)N(R30)2, -C(=O)OR30, -N(R30)2, -N(R30)C(=O)R31, - NHC(=O)N(R30)2, -N(R30)C(=O)OR31, -N(R30)C(=NCN)N(R30)2, -N(R30)C(=O)N(R30)SO2(R31), -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), -N(R30)S(O)2N(R30)2, -OR30, -OC(=O)N(R30)2, -SR30, -SO2N(R30)2, -SO2(R31), -OSO2(R31) y -OSi(R30)3; Y se selecciona del grupo que consiste en -(CR13R13)r-, -CHR13C(=O)-, -(CHR13)rO-, (CHR13)rN(R30)-, -C(=O)-, -C(=NR30)-, -C(=N-OR30)-, -CH(C(=O)NHR30)-, CH-heteroarilo-, -C(R13R13)rC(R13)=C(R13)-, -(CHR13)rC(=O)- y -(CHR13)rN(H)C(=O)-; o de manera alternativa Y es cicloalquilo, heterociclenilo, o heterociclilo donde el cicloalquilo, heterociclenilo o heterociclilo se fusiona con el anillo fenilo con marca D; los restos R13 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo. alquilarilo, cicloalquilo, alcoxi, arilo, heteroarilo, heterociclenilo, heterociclilo, espiroalquilo, -CN, -CO2H, -C(=O)R30, -C(=O)OR31, -C(=O)N(R30)2, -(CHR30)qOH, -(CHR30)qOR31, -(CHR30)qNH2, -(CHR30)qNHR31, - (CH2)qC(=O)NHR31, -(CH2)qSO2R31, -(CH2)qNSO2R31, -(CH2)qSO2NHR31, -NH2, -N(R30)2, -N(R30)C(=O)N(R30)2, -N(R30)SO2(R31), -OH, OR30 , -SO2N(R30)2 y -SO2(R31); los restos R30 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en H, alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, CN, -(CH2)qOH, -(CH2)qO-alquilo, -(CH2)qO-alquilarilo, (CH2)qO-arilo, -(CH2)qO-aralquilo, -(CH2)qO-cicloalquilo, (CH2)qNH2, (CH2)qNH-alquilo, -(CH2)qN(alquilo)2, - (CH2)qNH-alquilarilo, -(CH2)qNH-arilo, (CH2)qNH-aralquilo, -(CH2)qNH-cicloalquilo, -(CH2)qC(=O)NH-alquilo, (CH2)qC(=O)N(alquilo)2, -(CH2)qC(=O)NH-alquilarilo, -(CH2)qC(=O)NH-arilo, (CH2)qC(=O)NH-aralquilo, -(CH2)qC(=O)NH-cicloalquilo, -(CH2)qSO2- alquilo, -(CH2)SO2-alquilarilo, -(CH2)qSO2-arilo, -(CH2)qSO2-aralquilo, (CH2)qSO2-cicloalquilo, -(CH2)qNSO2-alquilo, -(CH2)qNSO2-alquilarilo, (CH2)qNSO2-arilo, -(CH2)qNSO2-aralquilo, -(CH2)qNSO2-cicloalquilo, -(CH2)qSO2NH-alquilo, -(CH2)qSO2NH- alquilarilo, -(CH2)qSO2NH-arilo, (CH2)qSO2NH-aralquilo, -(CH2)qSO2NH-cicloalquiIo, heterociclenilo, heterociclilo y heteroarilo; los restos R31 pueden ser iguales o diferentes, seleccionándose cada uno independientemente del grupo que consiste en alquilo, alquilarilo, arilo, aralquilo, cicloalquilo, -(CH2)qOH, -(CH2)qO-alquilo, -(CH2)qO-alquilarilo, -(CH2)qO-arilo, -(CH2)qO-aralquilo, -(CH2)qO-cicloalquilo, -(CH2)qNH2, -(CH2)qNH-alquiIo, (CH2)qN(alquilo)2, -(CH2)qNH-alquilarilo, -(CH2)qNH- arilo, (CH2)qNH-aralquilo, (CH2)qNH-cicloalquilo, -(CH2)qC(=O)NH-alquilo, -(CH2)qC(=O)N(alquilo)2, -(CH2)qC(=O)NH-alquilarilo, -(CH2)qC(=O)NH-arilo, -(CH2)qC(=O)NH-aralquilo, -(CH2)qC(=O)NH-cicloalquilo, -(CH2)qSO2-alquilo, (CH2)qSO2-alquilarilo, - (CH2)qSO2-arilo, -(CH2)qSO2-aralquilo, (CH2)qSO2-cicloalquilo, -(CH2)qNSO2-alquilo, -(CH2)qNSO2-alquilarilo, -(CH2)qNSO2-arilo, -(CH2)qNsO2-aralquilo, -(CH2)qNSO2-cicloalquilo, -(CH2)qSO2NH-alquilo, -(CH2)qSO2NH-alquilarilo. (CH2)qSO2NH-arilo, (CH2)qSO2NH-aralquilo, (CH2)qSO2NH-cicloalquilo, heterociclenilo, heterociclilo y heteroarilo; m es 0 a 4; n es 0 a 4; p es 0 a 5; cada q puede ser igual o diferente, seleccionándose cada uno independientemente de 1 a 5; y r es 1 a 4; con la salvedad de que no haya dos dobles enlaces adyacentes en ningun anillo y que cuando se sustituye un nitrogeno con dos grupos alquilo, dichos dos grupos alquilo se puedan unir opcionalmente entre si para formar un anillo.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65333805P | 2005-02-16 | 2005-02-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR054224A1 true AR054224A1 (es) | 2007-06-13 |
Family
ID=36636289
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AR20060100549A AR054224A1 (es) | 2005-02-16 | 2006-02-15 | Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 |
Country Status (17)
Country | Link |
---|---|
US (1) | US7868005B2 (es) |
EP (1) | EP1856098B1 (es) |
JP (1) | JP2008530220A (es) |
KR (1) | KR20070107060A (es) |
CN (1) | CN101142209A (es) |
AR (1) | AR054224A1 (es) |
AU (1) | AU2006214380A1 (es) |
BR (1) | BRPI0607946A2 (es) |
CA (1) | CA2598458A1 (es) |
IL (1) | IL185073A0 (es) |
MX (1) | MX2007009947A (es) |
NO (1) | NO20074698L (es) |
PE (1) | PE20061164A1 (es) |
RU (1) | RU2007134260A (es) |
TW (1) | TW200640903A (es) |
WO (1) | WO2006088921A2 (es) |
ZA (1) | ZA200706789B (es) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2297461T3 (es) | 2003-09-09 | 2008-05-01 | Fumapharm Ag | Uso de derivados del acido fumarico para tratar la insuficiencia cardiaca y el asma. |
JP4948395B2 (ja) | 2004-04-13 | 2012-06-06 | インサイト・コーポレイション | ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体 |
WO2006071958A1 (en) * | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
WO2006071875A1 (en) | 2004-12-29 | 2006-07-06 | Millennium Pharmaceuticals, Inc. | Compounds useful as chemokine receptor antagonists |
EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
EP1856097B1 (en) * | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CN101146793A (zh) * | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
CA2598418A1 (en) * | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
CA2598489A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
TW200714610A (en) | 2005-02-16 | 2007-04-16 | Univ Maryland | CXCR3 is a gliadin receptor |
CA2598456A1 (en) * | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
US7781437B2 (en) * | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
WO2007100610A2 (en) * | 2006-02-23 | 2007-09-07 | Merck & Co., Inc. | Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators |
AR059962A1 (es) * | 2006-03-21 | 2008-05-14 | Schering Corp | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 |
CA2658417A1 (en) * | 2006-07-14 | 2008-01-17 | Schering Corporation | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
AR064609A1 (es) * | 2006-12-22 | 2009-04-15 | Schering Corp | Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3. |
US20110112196A1 (en) | 2007-02-08 | 2011-05-12 | Matvey E Lukashev | Nrf2 screening assays and related methods and compositions |
US8835426B2 (en) * | 2007-02-26 | 2014-09-16 | Vitae Pharmaceuticals, Inc. | Cyclic urea and carbamate inhibitors of 11β-hydroxysteroid dehydrogenase 1 |
CN101678082B (zh) | 2007-03-26 | 2013-06-19 | 再生医药有限公司 | 使用cxcl9和抗cxcl9抗体促进骨髓保护和再生的方法 |
EP2183228B1 (en) * | 2007-07-26 | 2014-08-20 | Vitae Pharmaceuticals, Inc. | CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1 |
AR069207A1 (es) * | 2007-11-07 | 2010-01-06 | Vitae Pharmaceuticals Inc | Ureas ciclicas como inhibidores de la 11 beta - hidroxi-esteroide deshidrogenasa 1 |
CA2708303A1 (en) | 2007-12-11 | 2009-06-18 | Vitae Pharmaceuticals, Inc. | Cyclic urea inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW200934490A (en) * | 2008-01-07 | 2009-08-16 | Vitae Pharmaceuticals Inc | Lactam inhibitors of 11 &abgr;-hydroxysteroid dehydrogenase 1 |
JP5490020B2 (ja) * | 2008-01-24 | 2014-05-14 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状カルバゼート及びセミカルバジドインヒビター |
WO2009102428A2 (en) * | 2008-02-11 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | 1,3-OXAZEPAN-2-ONE AND 1,3-DIAZEPAN-2-ONE INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE 1 |
WO2009102460A2 (en) * | 2008-02-15 | 2009-08-20 | Vitae Pharmaceuticals, Inc. | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
PE20091576A1 (es) * | 2008-02-19 | 2009-11-05 | Sanofi Aventis | DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3 |
US20110105504A1 (en) * | 2008-03-18 | 2011-05-05 | Vitae Pharmaceuticals ,Inc. | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 |
CA2723039A1 (en) | 2008-05-01 | 2009-11-05 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291370B1 (en) | 2008-05-01 | 2013-11-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
EP2291373B1 (en) * | 2008-05-01 | 2013-09-11 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
JP5301563B2 (ja) | 2008-05-01 | 2013-09-25 | ヴァイティー ファーマシューティカルズ,インコーポレイテッド | 11β−ヒドロキシステロイドデヒドロゲナーゼ1の環状インヒビター |
NZ590495A (en) | 2008-07-25 | 2012-10-26 | Vitae Pharmaceuticals Inc | Dihydropyridin-phenyl-3-oxazinan-2-ones as inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
TW201016691A (en) | 2008-07-25 | 2010-05-01 | Boehringer Ingelheim Int | Inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
CA2744946A1 (en) | 2009-02-04 | 2010-08-12 | Boehringer Ingelheim International Gmbh | Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
TW201039034A (en) * | 2009-04-27 | 2010-11-01 | Chunghwa Picture Tubes Ltd | Pixel structure and the method of forming the same |
KR20120061771A (ko) * | 2009-04-30 | 2012-06-13 | 비타이 파마슈티컬즈, 인코포레이티드 | 11베타-하이드록시스테로이드 탈수소효소 1의 고리형 억제제 |
UA109255C2 (ru) | 2009-04-30 | 2015-08-10 | Берінгер Інгельхайм Інтернешнл Гмбх | Циклические ингибиторы 11бета-гидроксистероиддегидрогеназы 1 |
WO2011011123A1 (en) | 2009-06-11 | 2011-01-27 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 based on the 1,3 -oxazinan- 2 -one structure |
EP2448928B1 (en) | 2009-07-01 | 2014-08-13 | Vitae Pharmaceuticals, Inc. | Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
US8933072B2 (en) | 2010-06-16 | 2015-01-13 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
JP5813106B2 (ja) | 2010-06-25 | 2015-11-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 代謝障害の処置のための11−β−HSD1のインヒビターとしてのアザスピロヘキサノン |
WO2012000904A1 (en) | 2010-06-28 | 2012-01-05 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Pharmaceutical composition for use in the treatment of glaucoma |
GB201017345D0 (en) | 2010-10-14 | 2010-11-24 | Proximagen Ltd | Receptor antagonists |
CA2813671A1 (en) | 2010-11-02 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations for the treatment of metabolic disorders |
EP2771484A1 (en) | 2011-10-28 | 2014-09-03 | Galderma Research & Development | New leukocyte infiltrate markers for rosacea and uses thereof |
US9073856B2 (en) * | 2012-01-23 | 2015-07-07 | Eli Lilly And Company | Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors |
CN104093715B (zh) | 2012-02-02 | 2017-04-26 | 埃科特莱茵药品有限公司 | 4‑(苯并咪唑‑2‑基)‑噻唑化合物及相关氮杂衍生物 |
AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
WO2015011099A1 (en) | 2013-07-22 | 2015-01-29 | Actelion Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
CN103772262B (zh) * | 2014-02-24 | 2015-10-14 | 陕西理工学院 | 一种具有抗肿瘤活性的异邻苯二甲酰亚胺类化合物及其应用 |
AR099789A1 (es) | 2014-03-24 | 2016-08-17 | Actelion Pharmaceuticals Ltd | Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina |
AR103399A1 (es) | 2015-01-15 | 2017-05-10 | Actelion Pharmaceuticals Ltd | Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3 |
TR201900680T4 (tr) | 2015-01-15 | 2019-02-21 | Idorsia Pharmaceuticals Ltd | CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri. |
EA037555B1 (ru) | 2015-04-02 | 2021-04-13 | Проксимэйджен, Элэлси | Применение 6-{4-[1-(пропан-2-ил)пиперидин-4-ил]-1,4-диазепан-1-ил}-n-(пиридин-4-ил)пиридин-2-карбоксамида для лечения раковых заболеваний цнс |
WO2018129364A1 (en) | 2017-01-06 | 2018-07-12 | Palvella Therapeutics Llc | Anhydrous compositions of mtor inhibitors and methods of use |
WO2020010073A1 (en) | 2018-07-02 | 2020-01-09 | Palvella Therapeutics, Inc. | ANHYDROUS COMPOSITIONS OF mTOR INHIBITORS AND METHODS OF USE |
EP4349331A1 (en) * | 2021-06-04 | 2024-04-10 | Kyoto Pharmaceutical University | Novel amp-activated protein kinase activator |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07501063A (ja) | 1991-11-14 | 1995-02-02 | グラクソ、グループ、リミテッド | フィブリノーゲン依存性血小板凝集阻害剤としてのピペリジン酢酸誘導体 |
JPH07503459A (ja) * | 1992-01-21 | 1995-04-13 | グラクソ、グループ、リミテッド | 酢酸誘導体 |
US6124319A (en) | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
AR013693A1 (es) | 1997-10-23 | 2001-01-10 | Uriach & Cia Sa J | Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria |
PL203116B1 (pl) | 1999-05-04 | 2009-08-31 | Schering Corp | Piperazynopiperydynowa pochodna użyteczna jako antagonista CCR5, zawierająca ją kompozycja farmaceutyczna i jej zastosowanie |
AR033517A1 (es) * | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
US20020018776A1 (en) | 2000-04-14 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CXCR3 function |
EP1343505A1 (en) | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
US6469002B1 (en) | 2001-04-19 | 2002-10-22 | Millennium Pharmaceuticals, Inc. | Imidazolidine compounds |
GB0203994D0 (en) | 2002-02-20 | 2002-04-03 | Celltech R&D Ltd | Chemical compounds |
WO2003082335A1 (fr) | 2002-04-03 | 2003-10-09 | Sumitomo Pharmaceuticals Co., Ltd. | Nouveau dispositif de controle du sucre dans le sang et procede de criblage associe |
US7244555B2 (en) | 2002-05-14 | 2007-07-17 | Renovak Inc | Systems and methods for identifying organ transplant risk |
EP1554253A4 (en) | 2002-06-03 | 2006-09-20 | Smithkline Beecham Corp | IMIDAZOLIUM COMPOUNDS INHIBITORS OF CXCR3 |
CA2598418A1 (en) | 2005-02-16 | 2006-08-31 | Schering Corporation | Heteroaryl substituted pyrazinyl-piperazine-piperidines with cxcr3 antagonist activity |
EP1853583B1 (en) | 2005-02-16 | 2011-09-07 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
CN101146793A (zh) | 2005-02-16 | 2008-03-19 | 先灵公司 | 具有cxcr3拮抗剂活性的新的杂环取代了的吡啶或苯基化合物 |
CA2598456A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Heterocyclic substituted piperazines with cxcr3 antagonist activity |
CA2598489A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Piperazine-piperidines with cxcr3 antagonist activity |
EP1856097B1 (en) | 2005-02-16 | 2012-07-11 | Schering Corporation | Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
EP1856098B1 (en) | 2005-02-16 | 2012-08-01 | Schering Corporation | Pyrazinyl substituted piperazine-piperidines with cxcr3 antagonist activity |
US7781437B2 (en) | 2005-10-11 | 2010-08-24 | Schering Corporation | Substituted heterocyclic compounds with CXCR3 antagonist activity |
AR059962A1 (es) | 2006-03-21 | 2008-05-14 | Schering Corp | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 |
CA2658417A1 (en) | 2006-07-14 | 2008-01-17 | Schering Corporation | Heterocyclic substituted piperazine compounds with cxcr3 antagonist activity |
-
2006
- 2006-02-14 EP EP06735090A patent/EP1856098B1/en active Active
- 2006-02-14 BR BRPI0607946-6A patent/BRPI0607946A2/pt not_active IP Right Cessation
- 2006-02-14 CA CA002598458A patent/CA2598458A1/en not_active Abandoned
- 2006-02-14 WO PCT/US2006/005267 patent/WO2006088921A2/en active Application Filing
- 2006-02-14 MX MX2007009947A patent/MX2007009947A/es unknown
- 2006-02-14 US US11/354,138 patent/US7868005B2/en active Active
- 2006-02-14 KR KR1020077019297A patent/KR20070107060A/ko not_active Application Discontinuation
- 2006-02-14 AU AU2006214380A patent/AU2006214380A1/en not_active Abandoned
- 2006-02-14 JP JP2007556255A patent/JP2008530220A/ja active Pending
- 2006-02-14 RU RU2007134260/04A patent/RU2007134260A/ru not_active Application Discontinuation
- 2006-02-14 CN CNA2006800081411A patent/CN101142209A/zh active Pending
- 2006-02-14 PE PE2006000176A patent/PE20061164A1/es not_active Application Discontinuation
- 2006-02-15 TW TW095105141A patent/TW200640903A/zh unknown
- 2006-02-15 AR AR20060100549A patent/AR054224A1/es not_active Application Discontinuation
-
2007
- 2007-08-06 IL IL185073A patent/IL185073A0/en unknown
- 2007-08-15 ZA ZA200706789A patent/ZA200706789B/xx unknown
- 2007-09-14 NO NO20074698A patent/NO20074698L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR20070107060A (ko) | 2007-11-06 |
US7868005B2 (en) | 2011-01-11 |
NO20074698L (no) | 2007-11-16 |
AU2006214380A1 (en) | 2006-08-24 |
US20070054919A1 (en) | 2007-03-08 |
EP1856098A2 (en) | 2007-11-21 |
MX2007009947A (es) | 2007-09-26 |
EP1856098B1 (en) | 2012-08-01 |
RU2007134260A (ru) | 2009-03-27 |
ZA200706789B (en) | 2008-11-26 |
CA2598458A1 (en) | 2006-08-24 |
JP2008530220A (ja) | 2008-08-07 |
BRPI0607946A2 (pt) | 2009-10-20 |
CN101142209A (zh) | 2008-03-12 |
PE20061164A1 (es) | 2006-10-27 |
IL185073A0 (en) | 2007-12-03 |
WO2006088921A2 (en) | 2006-08-24 |
WO2006088921A3 (en) | 2006-11-02 |
TW200640903A (en) | 2006-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR054224A1 (es) | Piperazin- piperidinas sustituidas con pirazinilo con actividad antagonista de cxcr3 | |
AR055195A1 (es) | Piperazin-piridinas sustituidas con piridilo y fenilo con actividad antagonista de cxcr3 y composicion farmaceutica | |
AR053020A1 (es) | Pirazinil-piperazin-piperidinas sustituidas con heteroarilo con actividad antagonista de cxcr3 | |
AR054185A1 (es) | Piperazin- piperidinas sustituidas con piridilo y fenilo conectados por aminos con actividad antagonista de cxcr3 | |
AR064609A1 (es) | Piperazinas sustituidas, composiciones farmaceuticas que las comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor de quimiocinas cxcr3. | |
AR059962A1 (es) | Compuestos de piridina sustituida con heterociclos con actividad antagonista de cxcr3 | |
AR052911A1 (es) | Piperazinas sustituidas con heterociclos con actividad antagonista de cxcr3 | |
AR061975A1 (es) | Compuestos de piperazina 1,4-sustituida con actividad antagonista de cxcr3, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por el receptor de quimioquina cxcr3 | |
ES2281372T3 (es) | Inhibidores de proteina-quinasa triciclicos. | |
JP2011500702A5 (es) | ||
SI2986610T1 (en) | Bicyclic heterocycles as inhibitors of FGFR | |
RU2019115115A (ru) | Производные пиперидина в качестве ингибиторов убиквитин-специфической протеазы 7 | |
JP6507157B2 (ja) | Rhoキナーゼ阻害剤 | |
JP2023078421A (ja) | タンパク質チロシンホスファターゼ阻害剤 | |
MX2007001853A (es) | Combinaciones para el tratamiento de enfermedades que involucran la proliferacion celular. | |
KR20180052640A (ko) | 퀴놀론계를 대체하는 유도체 또는 그의 약학적으로 수용가능한 염 또는 입체이성체 및 이들의 의약용 조성물과 응용 | |
AU2007211620A1 (en) | Compounds for the inhibition of integrins and use thereof | |
AR032467A1 (es) | Derivados de piridina, procedimiento para prepararlos, el uso de dichos derivados para la preparacion de medicamentos y los medicamentos que contienen dichos derivados | |
ES2703934T3 (es) | Compuesto de pirrolo[2,1-f][1,2,4]triazina y procedimiento de preparación y aplicación del mismo | |
AR045260A1 (es) | Compuestos que contienen imidazo-oxima sustituidos | |
CA2504385A1 (en) | Thiadiazine compounds and uses thereof | |
RU2008136784A (ru) | Пиразолохинолоновые соединения, фармацевтическая композиция на их основе, способ ингибирования поли(адф-рибоза)полимеразы (parp) и способы лечения воспаления, сепсиса, септического шока и рака | |
AR057104A1 (es) | Diaminopirimidinas como moduladores de p2 x3 y p2x2 /3 y composicion farmaceutica | |
JP2016538316A5 (es) | ||
AR081626A1 (es) | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |